Clinical Trials Arena March 8, 2024
Jenna Philpott

As the number of approved cell and gene therapies is set to increase in the next ten years, what challenges do they present to the supply chain?

Last year, eight cell and gene therapies were approved in the US and EU, with the scope only continuing to increase. With this growth, experts gathered at Clinical Trial Supply (CTS) Europe to discuss the challenges these blockbuster treatments pose to the supply chain.

Leading the session “Current challenges in the supply chain and future trends”, global depot network director at the CRO SanaClis Allan van Konynenburg delved into trends such as artificial intelligence, blockchain, and cybersecurity, but “out of all trends, cell therapy is front and centre in terms of what’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Supply Chain, Technology
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
How Medicare Negotiated Drug Prices Compare to Other Countries
The Fed's Warnings On Inflation Are Bad News For Biotech Startups
AI Tech Firm SandboxAQ Adds $300M to Ramp Up Development of LQMs for Drug Discovery & More

Share This Article